Latest Machine Learning News

Integrated Research Limited reported an 18% revenue decline and a 51% drop in net profit for FY25, while unveiling a strategic pivot towards AI-driven product innovation and cloud services.

Beforepay Group Limited reported a strong FY25 with a 29% increase in net transaction margin and 14% revenue growth, driven by expanding user numbers and advances. The company continues to leverage AI-driven risk management while maintaining its ethical lending model.

Beforepay Group Limited reported a robust 74.5% increase in net profit after tax to $6.7 million for FY25, driven by growth in its core Pay Advance business, the launch of a Personal Loan product, and expansion of its AI-powered credit analytics division, Carrington Labs, in the US.

Australian Clinical Labs reported a 6.4% revenue increase and an 8.7% rise in underlying EBIT for FY25, maintaining disciplined growth and operational efficiency in a complex healthcare environment.

Praemium Limited reported robust FY25 results with revenue climbing 24.6% to $103 million and net profit after tax soaring 55% to $13.56 million, underpinned by strong growth in funds under administration and strategic product launches.

nib Holdings reported a solid FY25 with underlying operating profit of $239.2 million and 3.2% policyholder growth, driven by digital innovation and operational efficiencies. The Group’s strategic focus on core health insurance and adjacent services sets the stage for continued momentum into FY26.

INOVIQ Limited reported a $6.9 million net loss for FY25 while making significant strides in its exosome-based cancer diagnostics and therapeutics pipeline, including a breakthrough ovarian cancer screening test and promising CAR-exosome therapy results.

EPX Limited has successfully raised $2 million through a private placement, positioning itself to expand sales, explore acquisitions, and enhance its energy efficiency technology platform.

Tryptamine Therapeutics has secured an exclusive agreement with leading neuroscientists to develop a novel EEG-based brain entropy biomarker aimed at enhancing precision psychiatry for its psychedelic drug TRP-8803.

Artrya Limited reported a 17.2% increase in net loss to $16.4 million for FY25, while achieving FDA clearance and launching its AI-driven Salix platform in the U.S. market. The company also secured key commercial partnerships in Australia and raised $20 million in equity funding.

HUB24 Limited reported robust FY25 results, driven by a 34% surge in platform funds under administration and a 44% rise in underlying net profit after tax. The company expanded its adviser base and boosted dividends, reinforcing its leadership in Australia's wealth management technology sector.

HUB24 Limited reported robust FY25 results with revenue climbing 24% to $406.6 million and underlying net profit after tax soaring 44%. The company’s platform funds under administration grew 34%, underpinning a 47% increase in fully franked dividends.